National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

    NEXT STORY
    BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
    PREV STORY
    Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    NewLink Genetics Reports Third Quarter 2018 Financial Results and Announces Abstracts to Be Presented at Upcoming Medical Meetings

    Management to Host Conference Call Today at 4:30 p.m. ETAMES, Iowa, Nov. 01, 2018 (GLOBE ...

    author_avatar
    NASDAQ Market News

    Amendment to Sections 5 and 9(1) of the Articles of Association of Orion Corporation entered in the Trade Register

    ORION CORPORATION         STOCK EXCHANGE RELEASE 6 APRIL 2017 at 9.00 EET                      Amendment to Sections ...

    author_avatar
    NASDAQ Market News

    Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes

    author_avatar
    NASDAQ Market News